This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, N. J. Articles by Vaughan, D. E. Search for Related Content PubMed PubMed Citation Articles by Brown, N. J. Articles by Vaughan, D. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diets Hazardous Substances DB HYDROCORTISONE QUINAPRIL HYDROCHLORIDE SODIUM

(Hypertension. 1998;32:965-971.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Effect of Activation and Inhibition of the Renin-Angiotensin System on Plasma PAI-1

Nancy J. Brown; Mehmet A. Agirbasli; Gordon H. Williams; W. Reid Litchfield; Douglas E. Vaughan

From the Departments of Medicine and Pharmacology (N.J.B., M.A.A., D.E.V.), Vanderbilt University Medical Center, and the Veterans Affairs Medical Center (D.E.V.), Nashville, Tenn; and the Department of Medicine (G.H.W., W.R.L.), Brigham and Women's Hospital, Boston, Mass.

Abstract—Increased plasma renin activity (PRA) has been associated with an increased risk of myocardial infarction (MI), whereas angiotensin-converting enzyme (ACE) inhibition appears to reduce the risk of recurrent MI in patients with left ventricular dysfunction. These observations may be partially explained by an interaction between the renin-angiotensin system (RAS) and fibrinolytic system. To test this hypothesis, we examined the effect of salt depletion on tissue-type plasminogen activator (tPA) antigen and plasminogen activator inhibitor-1 (PAI-1) activity and antigen in normotensive subjects in the presence and absence of quinapril (40 mg BID). Under low (10 mmol/d) and high (200 mmol/d) salt conditions there was significant diurnal variation in PAI-1 antigen and activity and tPA antigen. Morning (8 AM through 2 PM) PAI-1 antigen levels were significantly higher during low salt intake compared with high salt intake conditions (ANOVA, F=5.8, P=0.048). PAI-1 antigen correlated with aldosterone (r=0.56, P<10^-7) during low salt intake. ACE inhibition significantly decreased 24-hour (ANOVA for 24 hours, F=6.7, P=0.04) and morning (F=24, P=0.002) PAI-1 antigen and PAI-1 activity (F=6.48, P=0.038) but did not alter tPA antigen. Thus, the mean morning PAI-1 antigen concentration was significantly higher during low salt intake than during either high salt intake or low salt intake and concomitant ACE inhibition (22.7±4.6 versus 16.1±3.3 and 16.3±3.7 ng/mL, respectively; P<0.05). This study provides evidence of a direct functional link between the RAS and fibrinolytic system in humans. The data suggest that ACE inhibition has the potential to reduce the incidence of thrombotic cardiovascular events by blunting the morning peak in PAI-1.

Key Words: renin • angiotensin II • plasminogen activator inhibitor 1 • fibrinolysis • tissue plasminogen activator • sodium • quinapril

This article has been cited by other articles:

				M. Cortinovis, N. Perico, D. Cattaneo, and G. Remuzzi Aldosterone and progression of kidney disease Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 133 - 143. [Abstract] [PDF]

				Y. Jeong, D. F. Chaupin, K. Matsushita, M. Yamakuchi, S. J. Cameron, C. N. Morrell, and C. J. Lowenstein Aldosterone activates endothelial exocytosis PNAS, March 10, 2009; 106(10): 3782 - 3787. [Abstract] [Full Text] [PDF]

				G. Remuzzi, D. Cattaneo, and N. Perico The Aggravating Mechanisms of Aldosterone on Kidney Fibrosis J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1459 - 1462. [Abstract] [Full Text] [PDF]

				C. Usalan and H. Buyukhatipoglu A Dynamic Comparative Study Concerning the Effects of Angiotensin-Converting Enzyme Inhibitors and Aldosterone Receptor Blockers on the Fibrinolytic System Clinical and Applied Thrombosis/Hemostasis, April 1, 2008; 14(2): 203 - 209. [Abstract] [PDF]

				M. Agirbasli, A. Cincin, and O. A Baykan Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 22 - 26. [Abstract] [PDF]

				N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]

				R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]

				H. L. Lazar All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors Circulation, January 1, 2008; 117(1): 6 - 8. [Full Text] [PDF]

				J. K. Devin, L. S. Blevins Jr., D. K. Verity, Q. Chen, J. R. Bloodworth Jr., J. Covington, and D. E. Vaughan Markedly Impaired Fibrinolytic Balance Contributes to Cardiovascular Risk in Adults with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3633 - 3639. [Abstract] [Full Text] [PDF]

				A. Briggs, B. Mihaylova, M. Sculpher, A. Hall, J. Wolstenholme, M. Simoons, J. Deckers, R. Ferrari, W. J Remme, M. Bertrand, et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Heart, September 1, 2007; 93(9): 1081 - 1086. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]

				T. J. Wang, P. Gona, M. G. Larson, D. Levy, E. J. Benjamin, G. H. Tofler, P. F. Jacques, J. B. Meigs, N. Rifai, J. Selhub, et al. Multiple Biomarkers and the Risk of Incident Hypertension Hypertension, March 1, 2007; 49(3): 432 - 438. [Abstract] [Full Text] [PDF]

				V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) Circulation, December 19, 2006; 114(25): 2850 - 2870. [Full Text] [PDF]

				P. G. Arndt, S. K. Young, K. R. Poch, J. A. Nick, S. Falk, R. W. Schrier, and G. S. Worthen Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways J. Immunol., November 15, 2006; 177(10): 7233 - 7241. [Abstract] [Full Text] [PDF]

				M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]

				M. P. Ponda and T. H. Hostetter Aldosterone Antagonism in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 668 - 677. [Full Text] [PDF]

				N. J. Brown, J. A.S. Muldowney III, and D. E. Vaughan Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition Hypertension, March 1, 2006; 47(3): 441 - 448. [Abstract] [Full Text] [PDF]

				A. W.J.H. Dielis, M. Smid, H. M.H. Spronk, K. Hamulyak, A. A. Kroon, H. ten Cate, and P. W. de Leeuw The Prothrombotic Paradox of Hypertension: Role of the Renin-Angiotensin and Kallikrein-Kinin Systems Hypertension, December 1, 2005; 46(6): 1236 - 1242. [Abstract] [Full Text] [PDF]

				J. C. Aldigier, T. Kanjanbuch, L.-J. Ma, N. J. Brown, and A. B. Fogo Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3306 - 3314. [Abstract] [Full Text] [PDF]

				J. Ma, F. Albornoz, C. Yu, D. W. Byrne, D. E. Vaughan, and N. J. Brown Differing Effects of Mineralocorticoid Receptor-Dependent and -Independent Potassium-Sparing Diuretics on Fibrinolytic Balance Hypertension, August 1, 2005; 46(2): 313 - 320. [Abstract] [Full Text] [PDF]

				K. Yamamoto, K. Takeshita, T. Kojima, J. Takamatsu, and H. Saito Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovasc Res, May 1, 2005; 66(2): 276 - 285. [Abstract] [Full Text] [PDF]

				H. L. Lazar Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089. [Abstract] [Full Text] [PDF]

				S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke Neurology, July 27, 2004; 63(2): 208 - 213. [Abstract] [Full Text] [PDF]

				P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]

				C. Sierra and L. M Ruilope Review: Role of the selective aldosterone receptor blockers in arterial hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 23 - 25. [Abstract] [PDF]

				J. P. Tsikouris, J. A. Suarez, G. E. Meyerrose, M. Ziska, D. Fike, and J. Smith Questioning a Class Effect: Does ACE Inhibitor Tissue Penetration Influence the Degree of Fibrinolytic Balance Alteration following an Acute Myocardial Infarction? J. Clin. Pharmacol., February 1, 2004; 44(2): 150 - 157. [Abstract] [Full Text] [PDF]

				M. Pretorius, L. J. Murphey, J. A. McFarlane, D. E. Vaughan, and N. J. Brown Angiotensin-Converting Enzyme Inhibition Alters the Fibrinolytic Response to Cardiopulmonary Bypass Circulation, December 23, 2003; 108(25): 3079 - 3083. [Abstract] [Full Text] [PDF]

				M. Epstein Aldosterone receptor blockade and the role of eplerenone: evolving perspectives Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1984 - 1992. [Full Text] [PDF]

				P. Sawathiparnich, L. J. Murphey, S. Kumar, D. E. Vaughan, and N. J. Brown Effect of Combined AT1 Receptor and Aldosterone Receptor Antagonism on Plasminogen Activator Inhibitor-1 J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3867 - 3873. [Abstract] [Full Text] [PDF]

				T. Mohri, N. Emoto, H. Nonaka, H. Fukuya, K. Yagita, H. Okamura, and M. Yokoyama Alterations of Circadian Expressions of Clock Genes in Dahl Salt-Sensitive Rats Fed a High-Salt Diet Hypertension, August 1, 2003; 42(2): 189 - 194. [Abstract] [Full Text] [PDF]

				D. E. Vaughan Plasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction Circulation, July 29, 2003; 108(4): 376 - 377. [Full Text] [PDF]

				A. H. Schmaier The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13. [Abstract] [Full Text] [PDF]

				W. F. Young Jr. Minireview: Primary Aldosteronism--Changing Concepts in Diagnosis and Treatment Endocrinology, June 1, 2003; 144(6): 2208 - 2213. [Abstract] [Full Text] [PDF]

				M. Pretorius, D. Rosenbaum, D. E. Vaughan, and N. J. Brown Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin Circulation, February 4, 2003; 107(4): 579 - 585. [Abstract] [Full Text] [PDF]

				S. I. McFarlane and J. R. Sowers Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 516 - 523. [Full Text] [PDF]

				N. J. Brown, S. Kumar, C. A. Painter, and D. E. Vaughan ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time Hypertension, December 1, 2002; 40(6): 859 - 865. [Abstract] [Full Text] [PDF]

				M. Eren, C. A. Painter, J. B. Atkinson, P. J. Declerck, and D. E. Vaughan Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1 Circulation, July 23, 2002; 106(4): 491 - 496. [Abstract] [Full Text] [PDF]

				D. A. Rosenbaum, M. Pretorius, J. V. Gainer, D. Byrne, L. J. Murphey, C. A. Painter, D. E. Vaughan, and N. J. Brown Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1023 - 1028. [Abstract] [Full Text] [PDF]

				N. Kobayashi, S. Nakano, S.-i. Mita, T. Kobayashi, T. Honda, Y. Tsubokou, and H. Matsuoka Involvement of Rho-Kinase Pathway for Angiotensin II-Induced Plasminogen Activator Inhibitor-1 Gene Expression and Cardiovascular Remodeling in Hypertensive Rats J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 459 - 466. [Abstract] [Full Text] [PDF]

				E. Svarstad, D. Hultstrom, D. Jensen, G. Jenssen, and B. M. Iversen Renal artery thrombosis with acute renal failure after withdrawal of angiotensin converting enzyme inhibitor: a case report Nephrol. Dial. Transplant., April 1, 2002; 17(4): 687 - 689. [Full Text] [PDF]

				P. Sawathiparnich, S. Kumar, D. E. Vaughan, and N. J. Brown Spironolactone Abolishes the Relationship between Aldosterone and Plasminogen Activator Inhibitor-1 in Humans J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 448 - 452. [Abstract] [Full Text] [PDF]

				N. J. Brown, A. Abbas, D. Byrne, J. A. Schoenhard, and D. E. Vaughan Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women Circulation, January 22, 2002; 105(3): 304 - 309. [Abstract] [Full Text] [PDF]

				S. Fava, J. Azzopardi, S. Ellard, and A. T. Hattersley ACE Gene Polymorphism as a Prognostic Indicator in Patients With Type 2 Diabetes and Established Renal Disease Diabetes Care, December 1, 2001; 24(12): 2115 - 2120. [Abstract] [Full Text] [PDF]

				C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF]

				J.-B. Michel Contrasting Outcomes of Atheroma Evolution: Intimal Accumulation Versus Medial Destruction Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1389 - 1392. [Full Text] [PDF]

				K. Kaikita, A. B. Fogo, L. Ma, J. A. Schoenhard, N. J. Brown, and D. E. Vaughan Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition Circulation, August 14, 2001; 104(7): 839 - 844. [Abstract] [Full Text] [PDF]

				M. E. Khalil, A. W. Basher, E. J. Brown Jr, and I. A. Alhaddad A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1757 - 1764. [Abstract] [Full Text] [PDF]

				N. J. Brown, L. J. Murphey, N. Srikuma, N. Koschachuhanan, G. H. Williams, and D. E. Vaughan Interactive Effect of PAI-1 4G/5G Genotype and Salt Intake on PAI-1 Antigen Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1071 - 1077. [Abstract] [Full Text] [PDF]

				T. Skurk, Y.-M. Lee, and H. Hauner Angiotensin II and Its Metabolites Stimulate PAI-1 Protein Release From Human Adipocytes in Primary Culture Hypertension, May 1, 2001; 37(5): 1336 - 1340. [Abstract] [Full Text] [PDF]

				L. Sironi, A. M. Calvio, L. Arnaboldi, A. Corsini, A. Parolari, M. de Gasparo, E. Tremoli, and L. Mussoni Effect of Valsartan on Angiotensin II-Induced Plasminogen Activator Inhibitor-1 Biosynthesis in Arterial Smooth Muscle Cells Hypertension, March 1, 2001; 37(3): 961 - 966. [Abstract] [Full Text] [PDF]

				M. Epstein Aldosterone as a determinant of cardiovascular and renal dysfunction J R Soc Med, January 8, 2001; 94(8): 378 - 383. [Full Text] [PDF]

				K. Lottermoser, H.-J. Hertfelder, M. Wehling, B. Schiermeyer, H. Vetter, and R. Dusing Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 357 - 360. [Abstract] [PDF]

				H.-C. Chen, J. L. Bouchie, A. S. Perez, A. C. Clermont, S. Izumo, J. Hampe, and E. P. Feener Role of the Angiotensin AT1 Receptor in Rat Aortic and Cardiac PAI-1 Gene Expression Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2297 - 2302. [Abstract] [Full Text] [PDF]

				D. C Felmeden and G. Y. Lip The renin-angiotensin-aldosterone system and fibrinolysis Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 240 - 244. [PDF]

				C. Labinjoh, D. E. Newby, P. Dawson, N. R. Johnston, C. A. Ludlam, N. A. Boon, and D. J. Webb Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man Cardiovasc Res, September 1, 2000; 47(4): 707 - 714. [Abstract] [Full Text] [PDF]

				D. E. Vaughan, N. J. Brown, D. N. E. R. Goodfield, D. D. E. Newby, and P. C. A. Ludlam Effects of Acute Angiotensin II Type 1 Receptor Antagonism and Angiotensin Converting Enzyme Inhibition on Plasma Fibrinolytic Parameters in Patients With Heart Failure Response Circulation, August 8, 2000; 102 (6): e43 - e43. [Full Text] [PDF]

				N. J. Brown, M. Agirbasli, and D. E. Vaughan Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans Hypertension, August 1, 1999; 34(2): 285 - 290. [Abstract] [Full Text] [PDF]

				N. J. Brown, J. V. Gainer, C. M. Stein, and D. E. Vaughan Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature Hypertension, June 1, 1999; 33(6): 1431 - 1435. [Abstract] [Full Text] [PDF]